Drug Interactions between crizotinib and Kineret
This report displays the potential drug interactions for the following 2 drugs:
- crizotinib
- Kineret (anakinra)
Interactions between your drugs
anakinra crizotinib
Applies to: Kineret (anakinra) and crizotinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.
MANAGEMENT: Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.
MONITOR: Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment with interleukin inhibitors may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs. In vitro studies showed that tocilizumab, an inhibitor of interleukin-6, has the potential to impact expression of various hepatic microsomal enzymes including CYP450 1A2, 2B6, 2C9, 2C19, 2D6, and 3A4. Its effects on CYP450 2C8 or transporters is unknown. In vivo studies with omeprazole (a substrate of CYP450 2C19 and 3A4) and simvastatin (a substrate of CYP450 3A4) showed decreases of up to 28% and 57% in systemic exposure, respectively, one week following a single dose of tocilizumab. A role for other interleukins such as IL-12, IL-17A, or IL-23 in the regulation of CYP450 enzymes has not been established, and it is not known whether antagonists of these interleukins (e.g., ixekizumab, secukinumab, ustekinumab) would similarly affect CYP450 metabolism.
MANAGEMENT: Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.
References
- "Product Information. Amevive (alefacept)." Biogen (2003):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc (2008):
- "Product Information. Stelara (ustekinumab)." Centocor Inc (2009):
- "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals (2009):
- "Product Information. Actemra (tocilizumab)." Genentech (2010):
- "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc. (2014):
- "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals (2015):
- "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company (2016):
Drug and food interactions
crizotinib food
Applies to: crizotinib
Do not consume grapefruit or grapefruit juice during treatment with crizotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of crizotinib to dangerous levels and cause an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with crizotinib. You may take crizotinib with or without food, but take it the same time each day. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.